Expression of CD4⁺T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis.

IF 1.7 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

Tohoku Journal of Experimental Medicine Pub Date : 2024-05-24 DOI:10.1620/tjem.2024.J029

Xiaoying Song, Yiping Yang, Jingjing Cui, Jing Sun, Jun Zhang, Lichang Gao, Jianqiang Liu

引用次数: 0

查看原文本刊更多论文

骨髓增生性疾病中 CD4+T 细胞的表达及 Ruxolitinib 治疗对预后的影响

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tohoku Journal of Experimental Medicine 医学-医学：内科

CiteScore

3.60

自引率

4.50%

发文量

171

审稿时长

1 months

期刊介绍： Our mission is to publish peer-reviewed papers in all branches of medical sciences including basic medicine, social medicine, clinical medicine, nursing sciences and disaster-prevention science, and to present new information of exceptional novelty, importance and interest to a broad readership of the TJEM. The TJEM is open to original articles in all branches of medical sciences from authors throughout the world. The TJEM also covers the fields of disaster-prevention science, including earthquake archeology. Case reports, which advance significantly our knowledge on medical sciences or practice, are also accepted. Review articles, Letters to the Editor, Commentary, and News and Views will also be considered. In particular, the TJEM welcomes full papers requiring prompt publication.

Expression of CD4+T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis.

Expression of CD4⁺T Cells in Myeloproliferative Diseases and the Effect of Ruxolitinib Treatment on Prognosis.